Eli Lilly's first quarter performance is expected to be influenced by the momentum of its GLP-1 products, with some outlets suggesting the launch of one such product has been muted. Meanwhile, competitor Novo Nordisk is also set to release earnings, with its stock potentially impacted by its own GLP-1 offerings and a booming weight-loss market. The companies' earnings updates may bring clarity to their respective stock outlooks, which some outlets suggest have significant valuation upside.